Publications by authors named "Rosa Maria di Mauro"
Introduction: KRAS mutation the most common molecular alteration in advanced non-small cell lung cancer (NSCLC) and is associated with an unfavourable prognosis, largely due to the lack of targeted therapeutic options for the majority of the KRAS mutated isoforms. The landscape of NSCLC treatment has expanded with the introduction of immune checkpoint inhibitors (ICIs). Nonetheless, data regarding the efficacy of ICI in NSCLC patients harbouring KRAS mutations are conflicting.
View Article and Find Full Text PDFBackground: Immunotherapy (IO) single agent or combined with chemotherapy (CT-IO) is the standard treatment for advanced non-small-cell lung cancer (aNSCLC) without driver alterations. IO efficacy in patients with novel driver alterations is not well reported.
Materials And Methods: Data of aNSCLC patients treated with IO or CT-IO in any line from January 2016 to September 2022 were retrospectively collected.
Article Synopsis
- - The STYLE trial tested the effectiveness and safety of sunitinib in patients with advanced or recurrent type B3 thymoma and thymic carcinoma, as these conditions have limited treatment options.
- - The results showed a 0% objective response rate in thymoma and a 21.7% response rate in thymic carcinoma after the treatment, with high disease control rates but also significant adverse effects reported.
- - The findings suggest that sunitinib can be an effective second-line treatment for thymic carcinoma, but it may cause serious side effects that might need dose adjustments.
Background: Immune-checkpoint inhibitors (ICIs) have significantly improved outcome of advanced non-small cell lung cancer (aNSCLC) patients. However, their efficacy remains uncertain in uncommon histologies (UH).
Materials And Methods: Data from ICI treated aNSCLC patients (April,2013-January,2021) in one Institution were retrospectively collected.
Background: Beyond programmed death ligand 1 (PD-L1), no other biomarkers for immunotherapy are used in daily practice. We previously created EPSILoN (Eastern Cooperative Oncology Group performance status (ECOG PS), smoking, liver metastases, lactate dehydrogenase (LDH), neutrophil-to-lymphocyte ratio (NLR)) score, a clinical/biochemical prognostic score, in 154 patients treated with second/further-line immunotherapy. This study's aim was to validate EPSILoN score in a different population group.
View Article and Find Full Text PDF